Judge Slashes Bayer's Massive $2B Roundup Verdict To $400M
Judge Slashes Bayer's Massive $2B Roundup Verdict To $400M
A Pennsylvania judge on Tuesday drastically reduced a $2.25 billion verdict against Bayer AG (OTC:BAYRY), cutting it down to $400 million in a case involving a man who claimed he developed cancer from using the company's Roundup weedkiller.
宾夕法尼亚的一位法官在周二大幅减少了拜耳（场外交易：拜耳(adr)）22.5亿美元的裁决结果，将其削减至4亿美元，该案牵涉到一名声称因使用该公司的Roundup杀草剂患癌症的男子。
The jury in the Philadelphia Court of Common Pleas had initially awarded John McKivison $250 million in compensatory damages and $2 billion in punitive damages, finding that his non-Hodgkin's lymphoma was caused by long-term use of Roundup at his home.
费城普通陪审法院陪审团最初授予约翰·麦克伊维森2.5亿美元的补偿赔偿金和20亿美元的惩罚性赔偿金，认定他非霍奇金淋巴瘤是由于在家长期使用Roundup所致。
However, Judge Susan Schulman later adjusted the damages to $50 million in compensatory and $350 million in punitive, citing Bayer's challenges.
然而，法官苏珊·舒尔曼后来将赔偿金调整为5000万美元的补偿和3.5亿美元的惩罚性赔偿金，理由是拜耳面临的挑战。
Bayer intends to appeal to the Superior Court of Pennsylvania, arguing that the trial included misleading and "inflammatory" testimony. Reuters noted that the company also called for legislative reform to shield companies that comply with federal labeling standards.
拜耳打算上诉至宾夕法尼亚高级法院，称审判包括具有误导性和“煽动性”的证言。路透社指出，该公司还呼吁立法改革，以保护遵守联邦标签标准的公司。
McKivison's legal team expressed satisfaction that the jury's decision to link Roundup to cancer was upheld.
麦克伊维森的法律团队对陪审团将Roundup与癌症联系在一起的决定感到满意。
However, they plan to appeal for the reinstatement of the original $2.25 billion verdict, stating that the reduction deviates from established Pennsylvania law.
然而，他们计划上诉，寻求恢复原先的22.5亿美元的裁决结果，并表示这一减少偏离了宾夕法尼亚州既定的法律。
Despite numerous studies indicating that glyphosate, the active ingredient in Roundup, is safe for human use, the product has faced extensive legal challenges.
尽管有多项研究表明Roundup的活性成分草甘膦对人类使用是安全的，但该产品面临着广泛的法律挑战。
Roundup, once widely used in U.S. households, saw its home-use sales phased out by Bayer last year.
曾经被广泛用于美国家庭的Roundup，在去年被拜耳逐步停止使用。
Bayer has faced over 165,000 claims in the U.S. alleging that Roundup causes non-Hodgkin's lymphoma. Although Bayer has won 14 of the last 20 trials, recent losses have led to over $4 billion in verdicts, shaking investor confidence and company hopes for an end to the litigation.
拜耳在美国面临超过16.5万个声称Roundup导致非霍奇金淋巴瘤的诉讼。尽管拜耳在过去的20次审判中赢得了14次，但最近的败诉导致了超过40亿美元的赔偿金，动摇了投资者的信心，也削弱了公司结束诉讼的希望。
In 2020, Bayer settled many pending cases for up to $9.6 billion, but future claims remain unresolved, with more than 50,000 still pending.
2020年，拜耳为许多待处理的案件达成了高达96亿美元的和解，但未来的索赔仍未解决，仍有超过5万个案件等待裁决。
Price Action: BAYRY shares closed at $7.79 on Tuesday.
股价行情：BAYRY股票周二收于7.79美元。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免责声明：本内容部分使用人工智能工具生成，并经Benzinga编辑审核发布。
Photo via Wikimedia Commons
照片通过Wikimedia Commons